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tion cost compared to generic risperidone. CONCLUSIONS: Treatment of early 
responders was more cost-effective than the treatment of early non-responders to 
atypical antipsychotic therapy. The treatment of early non-responders who switched 
to olanzapine was more cost-effective than treatment of early non-responders main-
tained on generic risperidone.
PMH52
ECONOMIC ANALYSIS OF ESCITALOPRAM (GENERIC DRUG) IN MAJOR 
DEPRESSIVE DISORDER (MDD)
Walczak J, Nogas G, Garbacka M, Obrzut G, Pieniazek I
Arcana Institute, Cracow, Poland
OBJECTIVES: The purpose was to conduct an economic analysis of escitalopram 
(generic drug) versus sertraline and venlafaxine as standard regimen in treatment of 
major depressive disorder (MDD) in Poland. METHODS: Due to lack of statistically 
signiﬁcant differences in comparisons of escitalopram with sertraline and escitalopram 
with venlafaxine, economic proﬁtability estimation was conducted as a cost-minimi-
sation analysis (CMA). Decision model was created by using TreeAge® Pro. Data 
concerning efﬁcacy and safety of compared therapies was based on the clinical-
effectiveness analysis, which was conducted as systematic literature review. Total 
costs of analysed therapies were estimated from the perspective of both payers in 
Poland (National Health Fund and patient) and also from the social perspective. The 
time horizon of the analysis was 6 months. The costs were not discounted. The stabil-
ity of results was checked in one-way and probabilistic sensitivity analyses. Addition-
ally, optimistic and pessimistic scenarios were prepared. RESULTS: Based on the 
assumptions that clinical effects of compared treatment strategies are the same, the 
results of the cost-minimisation analysis are as following: treatment of one patient 
using escitalopram in the 6 month time horizon is 12.71 PLN more expensive then 
sertraline therapy and 135.95 PLN cheaper then therapy with venlafaxine. One-way 
sensitivity analysis conducted for comparison of escitalopram versus sertraline 
showed that results are sensitive on the prices of medicaments. The sensitivity analysis 
conducted for comparison of escitaloprom versus venlafaxine showed the stability of 
basic results. Therapy with escitalopram is cheaper than with venlafaxine for all 
parameters took into account in the sensitivity analysis. CONCLUSIONS: Escitalo-
pram (generic drug) is costly comparable to sertraline and cheaper option of treatment 
in comparison with venlafaxine in the treatment of major depressive disorder in the 
6 month time horizon.
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ESTIMATION OF UTILITY GAINED FROM METHADONE MAINTENANCE 
TREATMENT FOR OPIOID DEPENDENCE
Liao DL1, Wang JD1, Huang CY2, Chen PC3
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OBJECTIVES: Opioid addiction is a chronic brain disease with severe withdrawal 
symptoms and decompensated condition in the vicious circle of compulsive drug 
seeking behavior, including needle sharing, psychosocial dysfunction, and criminal 
acts due to ﬁnancial decompensation. Methadone maintenance therapy is the service 
under the concept of harm reduction. We analyzed the estimated utility of prevention 
in the implementation of methadone maintenance therapy introduced in Taiwan since 
2006. METHODS: By using the methadone registry data and the estimation of inci-
dence rates of decompensation with versus without methadone maintenance, the 
expected number of decompensated cases reduced by harm reduction can be calcu-
lated. The utility possibly gained is estimated based on assumption of different values 
of quality of life (QOL) for the decompensation. RESULTS: Based on the imprisoned 
registry of Ministry of Justice and estimations of the Center for Diseases Control, the 
number of heroin addicts in Taiwan was about 100,000, with a total of 15,000 regu-
larly in prison. The yearly number of methadone registry cases reached 15,500 by the 
year-end of 2008. Assuming that annual incidence rates of decompensation were about 
0.1 and 0.7 for heroin addicts with and without methadone therapy, then the annual 
expected number prevented by such treatments would be 9000 with a possible gain 
of utility of 1800 and 4500 QALY (quality-adjusted life year), respectively, depending 
on the reduced utility of 0.2–0.5 for the QOL among decompensated cases. CONCLU-
SIONS: As the annual cost for administration of methadone program was about 
40,000 NTD, which leads to an incremental cost of 66,640 to 166,600 NTD (1 USD 
= 32 NTD) per QALY, without counting the cost of possible harm produced to the 
society by decompensated behaviors. With improved accessibility of methadone main-
tenance therapy, the utility of prevention for the decompensation of heroin addiction 
may be further increased.
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ECONOMIC EVALUATION OF ESCITALOPRAM TO TREAT MAJOR 
DEPRESSIVE DISORDER
Lachaine J1, Beauchemin C1, Legault M2
1University of Montreal, Montreal, QC, Canada, 2Lundbeck Canada Inc., Montreal, QC, 
Canada
OBJECTIVES: Major depressive disorder (MDD) is a psychiatric condition principally 
characterized by depressive mood, loss of appetite, decreased interest in daily activities, 
sleep, behavioural or attentional disorders, diminution of energy, and feelings of guilt. 
Because MDD is associated with substantial health care costs and productivity losses, 
it wields a considerable economic impact. The aim of this study was to assess, in the 
Canadian context, the economic impact of escitalopram in the treatment of MDD. 
METHODS: A cost-utility analysis was performed over a one-year time horizon from 
societal and health care system perspectives in Canada. A decision tree was developed 
to compare the cost per quality adjusted life year (QALY) associated with the use of 
escitalopram and citalopram. The decision tree, which included patients with MDD 
who had received escitalopram or citalopram as initial treatment, takes into account 
the probability of initial and subsequent treatment remission, of relapse, of suicide 
attempts, and of suicide-related death. Costs included were those of the antidepressant 
drugs, medical visits and hospitalizations, and those associated with remission/non-
remission, relapses, suicide attempts and suicide-related deaths. Costs related to pro-
ductivity loss and societal costs associated with suicide-related deaths were also 
included in the analysis with the societal perspective. Utility values associated with 
remission and non-remission were obtained from the literature. RESULTS: From a 
health care perspective, the incremental cost-utility ratio of escitalopram compared to 
citalopram was estimated at $12,869/QALY. From a societal perspective, escitalopram 
provided more QALYs (+0.0085 QALY/patient) and entailed fewer costs (−$144.70/
patient) compared to citalopram. Deterministic and probabilistic sensitivity analyses 
conﬁrmed the robustness of the base-case results. CONCLUSIONS: The results of 
this economic evaluation indicate that escitalopram is a more cost-effective alternative 
than citalopram to treat MDD from both the health care system and societal 
perspectives.
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CANADIAN COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING 
RISPERIDONE VERSUS ORAL ATYPICAL AND CONVENTIONAL DEPOT 
ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA AT HIGH-RISK 
OF NON-COMPLIANCE: UPDATED BASED ON NEW CLINICAL DATA
Lam A1, Heeg B2
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OBJECTIVES: The Canadian cost-effectiveness analysis of long-acting risperidone 
versus oral atypical and conventional depot antipsychotics in the treatment of schizo-
phrenia was updated based on results from a study comparing long-acting risperidone 
to depot zuclopenthixol. METHODS: An extensive pharmacoeconomic discrete event 
model was developed to estimate the costs and health beneﬁts of patients treated with 
long-acting risperidone versus oral atypical and conventional depot antipsychotics in 
the treatment of patients with schizophrenia at high-risk of non-compliance over a 
ﬁve-year period. In the original analysis, oral risperidone was considered in the oral 
atypical arm and haloperidol decanoate was considered in the conventional depot arm. 
At the time of the original analysis there were no head-to-head clinical studies which 
compared long-acting risperidone to conventional depots. Since, an open-label, ran-
domized, controlled, assessor-blinded, six-month study comparing long-acting risperi-
done to depot zuclopenthixol has been published. Using these study results, the model 
was updated to consider depot zuclopenthixol as the treatment for the depot compara-
tor arm. The comparator of oral risperidone for the oral atypical arm remained the 
same. RESULTS: The model projected the ﬁve-year cumulative direct costs of 
$155,601, $178,153, and $182,942 (discounted) for long-acting risperidone, oral 
risperidone, and depot zuclopenthixol, respectively. Thus, treatment with long-acting 
risperidone saved approximately $22,552 and $27,341 (discounted) over 5 years 
compared to oral risperidone and depot zuclopenthixol. Moreover, long-acting ris-
peridone resulted in greater decreases in the number of relapses, total time spent in 
psychosis and a greater increase in quality-adjusted-life-years (QALYs) compared to 
oral risperidone or depot zuclopenthixol. Hence, long-acting risperidone is the domi-
nant strategy, being more effective and less costly than oral risperidone or depot 
zuclopenthixol. CONCLUSIONS: Consistent with the original analysis, the current 
analysis demonstrates that long-acting risperidone is a cost-effective option which 
results in better clinical outcomes and lower total health care costs than oral risperi-
done or depot zuclopenthixol.
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OBJECTIVES: This analysis considers the impact of ADHD in adults on 1) labor force 
status, and 2) workplace absenteeism and presenteeism in the US. METHODS: Data 
from the 2009 US National Health and Wellness Survey (NHWS) were used to identify 
all those in the labor force 18 to 49 years of age with a diagnosis of attention deﬁcit 
disorder (ADD) or ADHD. The analysis was in two stages: 1) an evaluation of the 
prevalence of adult ADHD (n = 40,428), and 2) the estimation of logistic regressions 
to assess the contribution of unmedicated/medicated ADHD to labor force status and 
the estimation of ordered probit regressions (n = 25,862) to assess the contribution 
of unmedicated/medicated ADHD to absenteeism and presenteeism. Additional vari-
ables that are considered are socio-demographic status and health risk factors, together 
with the Charlson Comorbidity Index (CCI). RESULTS: An estimated 2.7% had 
diagnosed ADHD. This had a signiﬁcant negative impact on labor force participation 
(odds ratio 0.817), although medicated ADHD had no impact. The presence of 
unmedicated ADHD and medicated ADHD were, however, signiﬁcant at the 1% level 
in both the absenteeism and presenteeism models. Odds ratios in the absenteeism 
model were 4.79 for those with unmedicated ADHD and 3.27 for those with medi-
cated ADHD. These were of a similar magnitude to odds ratios for health risk factors 
(obesity 3.40 and morbid obesity 6.34) but less than the CCI odds ratio 17.43. In the 
presenteeism model, the odds ratios were also signiﬁcant at the 1% level at 8.07 for 
medicated and 6.99 for unmedicated ADHD. CONCLUSIONS: The presence of 
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unmedicated, ADHD in adults has a negative impact on labor force participation in 
the US. Irrespective of whether or not the ADHD is medicated, its presence also has 
a signiﬁcant impact on increased absenteeism and presenteeism.
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PSYCHIATRIC-RELATED HEALTH CARE COSTS AND RISK OF 
HOSPITALIZATION AMONG MEDICAID PATIENTS WITH TYPE I 
BIPOLAR DISORDER WHO RELAPSE FREQUENTLY
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OBJECTIVES: To examine psychiatric-related health care costs and inpatient utiliza-
tion among patients with type I bipolar disorder who relapse frequently within a large 
Medicaid database. METHODS: A large multistate Medicaid claims database (Mar-
ketScan®) was used to identify patients aged 18 to 64 years with type I bipolar disor-
der; ≥1 prescription claim for lithium, an anticonvulsant, or an antipsychotic between 
January 1, 2004 and December 31, 2005; and ≥24 months’ continuous enrollment. 
Frequent relapse (FR) was deﬁned as ≥2 clinically signiﬁcant events (CSEs) occurring 
during a 12-month identiﬁcation period beginning with the initial CSE (if any). CSEs 
included emergency room (ER) visits or inpatient hospitalizations (IH) with a principal 
diagnosis of bipolar disorder or a change in bipolar disorder medication(s). Patients 
were followed for a subsequent 12-month period to evaluate health care utilization 
and associated costs. Generalized linear modeling was used to estimate the impact of 
FR on psychiatric-related health care costs; logistic regression was used to estimate 
the impact of FR on psychiatric IH and ER visits. RESULTS: Of 5527 patients with 
type I bipolar disorder, 53% relapsed frequently. Of the patients with FR, 75% were 
female. Close to one-third (29%) of patients who relapsed frequently in the identiﬁca-
tion period also relapsed frequently in the follow-up period. During the 12-month 
follow-up period, patients with FR had higher adjusted per-patient psychiatric-related 
health care costs (mean $6014 vs $3495; P < 0.001), 3.7 times greater odds of psy-
chiatric IH (P < 0.01), and 3.1 times greater odds of psychiatric-related ER visits (P 
< 0.01) than patients who did not relapse frequently. CONCLUSIONS: Medicaid 
patients with type I bipolar disorder who relapsed frequently had signiﬁcantly higher 
adjusted psychiatric-related health care costs and greater odds of IH and ER events 
in a subsequent period than patients who did not relapse frequently. Supported by 
funding from Ortho-McNeil Janssen Scientiﬁc Affairs, LLC.
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ASSESSMENT OF HEALTH CARE UTILIZATION AND COST  
AMONG PATIENTS WITH BIPOLAR I DISORDER TREATED  
WITH ANTIPSYCHOTIC THERAPY IN A MULTISTATE  
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OBJECTIVES: To estimate the rates and costs of all-cause and psychiatric-related 
hospitalizations and ER visits among patients with bipolar I disorder. METHODS: 
Retrospective cohort analysis of multistate Medicaid patients who were aged ≥18 
years, had ≥1 inpatient or ≥2 outpatient medical claims indicating bipolar I disorder 
(ICD-9-CM codes 296.0X-296.1X, 296.4X-296.7X), and ﬁlled ≥1 prescription for an 
antipsychotic medication between January 1, 2004, and December 31, 2006. Patients 
were followed for 1 year from the date of ﬁrst, or index, antipsychotic prescription. 
Patients were required to be continuously eligible for Medicaid without dual Medicare 
eligibility from 1 year before (baseline) through 1 year after (follow-up) index, and 
were required to receive ≥1 additional antipsychotic claim during follow-up to ensure 
a treated population. Descriptive statistics were generated on the use and costs 
(proxied by Medicaid payments) of hospitalizations and ER visits, both all-cause and 
psychiatric-related (ICD-9-CM 290.XX-319.XX). RESULTS: 9410 patients met study 
eligibility criteria. Mean (±SD) patient age was 38.0 (±11.9) years, 74% were female, 
and 75% were white. Approximately 31% and 57% had preexisting diagnoses of 
substance abuse and psychiatric conditions, respectively. During follow-up, 40% of 
patients were hospitalized for any reason (37% with a psychiatric diagnosis). Patients 
had an average (±SD) of 0.9 (±1.7) all-cause and 0.8 (±1.6) psychiatric-related hospi-
talizations. All-cause and psychiatric-related ER visits occurred in 67% and 29% of 
patients, with an average (±SD) of 6.1 (±10.9) and 0.9 (±2.7) visits per patient, 
respectively. Average (±SD) costs were $6986 (±$10,374) and $6916 (±$10,288) for 
all-cause and psychiatric-related hospitalizations, and $158 (±$218) and $256 (±$416) 
for all-cause and psychiatric-related ER visits, respectively. CONCLUSIONS: Hospi-
talizations, ER visits, and costs were substantial among patients with bipolar I disor-
der. Studies investigating predictors of hospitalizations and ER visits in this patient 
population are warranted. Supported by funding from Ortho-McNeil Janssen Scien-
tiﬁc Affairs, LLC.
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OBJECTIVES: It is important for the management of a psychiatric hospital having an 
acute-care ward to estimate medical practice revenues under different conditions. We 
developed a system dynamics (SD) simulation model for the treatment of acute schizo-
phrenia to investigate the effect of the treatment of patients with acute schizophrenia 
on the hospital management. METHODS: We developed an SD simulation model for 
patient admission and discharge at a psychiatric acute-care ward. The model assumed 
an imaginary, newly built psychiatric hospital consisting of 3 types of wards: a psy-
chiatric acute-care ward, a general psychiatric ward, and a psychiatric nursing-care 
ward. The rates of discharge were set at 40%/month, 30%/month and 20%/month 
for a psychiatric acute-care ward, a general psychiatric ward, and a psychiatric 
nursing-care ward, respectively. The number of newly admitted patients was supposed 
to be 10 per month. We compared the total medical practice revenues at 36 months. 
RESULTS: Up to 9 months of outpatient treatment, the total medical practice revenues 
increased and then decreased at 12 months. A 2-way sensitivity analysis on the ﬁrst-
time admissions and the duration of outpatient treatment revealed that the total 
medical practice revenues were higher when the number of newly admitted patients 
was 5–11 at 9 months of outpatient management; however, when the number of newly 
admitted patients was 12–15, the maximum medical practice revenue was obtained 
at 12 months of outpatient management. CONCLUSIONS: Total medical practice 
revenues change depending on the rates of discharge from a psychiatric acute-care 
ward, the duration of outpatient treatment and the number of newly admitted patients. 
A budget plan for each psychiatric hospital having a psychiatric acute-care ward 
should be based on the calculation of those parameters and a systematic approach to 
patient management is important.
MENTAL HEALTH – Patient-Reported Outcomes Studies
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ADHERENCE TO MEDICATION FOR ATTENTION DEFICIT 
HYPERACTIVITY DISORDER (ADHD):DOES THE TIMEFRAME MATTER?
Barner JC, Khoza S, Oladapo A
The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: ADHD medication users frequently take ‘drug holidays’ during the 
summer months. The study objective was to compare ADHD medication adherence 
for an entire year (EY-365 days) and the school year (SY-270 days) by medication 
class and type. METHODS: Continuously enrolled Texas Medicaid children (≤18 
years) who had ≥2 prescription claims for an ADHD medication served as the study 
population. EY and SY (September 1-May 31) prescription claims were extracted from 
July 2002-December 2008. Prescription claims were grouped by medication class 
[immediate release(IR), extended release(ER), long-acting(LA), non-stimulant(NS)]; 
and medication type [stimulant(S) vs. non-stimulant(NS)]. Adherence, assessed by 
medication possession ratio (MPR) using a ﬁxed interval denominator, was measured 
both continuously and dichotomously (80%). T-tests, ANOVAs and chi-square were 
employed to determine differences between groups. RESULTS: Overall mean adher-
ence for EY (n = 62,789) was 49.8 ± 30.3 and SY (n = 50,842) was 62.2 ± 26.2. For 
EY, mean medication class adherence was not signiﬁcantly different between NS (52.5 
± 30.9) and ER (52.1 ± 30.2); however, LA (47.6 ± 30.9) and IR (37.2 ± 27.1) were 
signiﬁcantly lower (p < 0.0001). Regarding SY, adherence was not signiﬁcantly dif-
ferent among ER (63.7 ± 26.0), LA (63.5 ± 23.8) and NS (62.9 ± 27.0), while IR (52.8 
± 24.7) was signiﬁcantly lower (p < 0.0001). When adherence was dichotomized, EY 
medication class adherence differed signiﬁcantly (p < 0.0001): NS(25.8%), ER(24.1%), 
LA(21.2%), IM(9.8%). Similarly, SY differed signiﬁcantly (p < 0.0001): NS(30.8%), 
ER(30.0%), LA(25.6%), IM(16.2%). NS had signiﬁcantly higher mean adherence 
than S, respectively: EY(52.5 ± 30.9 vs. 49.4 ± 30.2; p < .0001) and SY(62.9 ± 27.0 
vs. 62.1 ± 26.1; p < .01). When dichotomized, results were similar (p < .0001): 
EY(25.8% vs. 21.5%) and SY(30.8% vs. 27.9%). CONCLUSIONS: Subjects were 
more adherent during SY compared to EY. Medication class mean adherence differed 
depending on timeframe used. For analyses comparing NS and S, NS had signiﬁcantly 
higher adherence, however for SY mean adherence, the difference may not be practi-
cally signiﬁcant. Due to unique patient medication-taking behaviors, ADHD medica-
tion adherence differs depending on the timeframe used.
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ADHERENCE AND PERSISTENCE WITH MEDICATION THERAPY IN 
PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A REAL-WORLD 
COMPARISON OF BRANDED ANTIDEPRESSANTS AND GENERIC SSRIS
Chen Y, Liu X, Faries D, Watson PR
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Adherence and persistence with prescribed medication is important in 
the treatment of major depressive disorder (MDD). This study compared adherence 
and persistence of 3 branded antidepressants (duloxetine, venlafaxineXR, and esci-
talopram) and generic selective serotonin reuptake inhibitors (SSRIs) in the real-world 
treatment of MDD. METHODS: A total of 44,026 MDD patients (18 to 64 years) 
